Search results
Results From The WOW.Com Content Network
Direct thrombin inhibitors (DTIs) are a class of medication that act as anticoagulants (delaying blood clotting) by directly inhibiting the enzyme thrombin (factor IIa). Some are in clinical use, while others are undergoing clinical development.
Direct oral anticoagulants (DOACs)—dabigatran (Pradaxa), rivaroxaban (Xarelto), apixaban (Eliquis), edoxaban (Savaysa), and betrixaban (Bevyxxa) are anticoagulation pharmacotherapy used for the prevention of thrombosis in several cardiovascular contexts. 1 DOACs are categorized into 2 main classes: oral direct factor Xa inhibitors (ie ...
Direct thrombin inhibitors attach to thrombin directly and inhibit it, or keep it from working, like their name says. Thrombin is an enzyme that plays a key role in clotting, so blocking it has a big impact.
Direct thrombin inhibitors (DTIs) are a new class of anticoagulants that bind directly to thrombin and block its interaction with its substrates. Four parenteral DTIs have been approved by...
This topic review discusses practical aspects of the use of direct thrombin inhibitors (oral and parenteral) and oral direct factor Xa inhibitors, along with a brief mention of other anticoagulants in development.
Currently, four parenteral direct inhibitors of thrombin activity are FDA-approved in North America: lepirudin, desirudin, bivalirudin and argatroban. Of the new oral DTIs, dabigatran etexilate is the most studied and promising of these agents.
Several direct thrombin inhibitors (DTIs) have been approved for clinical use in the prevention of thrombosis, for example desirudin. However, those agents that still require parenteral administration are not suitable for, ichronic use, and the need for development of efficient, safe, convenient, and predictable oral anticoagulants led to ...
DOACs are categorized into 2 main classes: oral direct factor Xa inhibitors (ie, rivaroxaban, apixaban, edoxaban, and betrixaban) and direct thrombin inhibitors (ie, dab-igatran). In 2010, the US Food and Drug Administration (FDA) approved its first DOAC, dabigatran, followed by rivaroxaban, apixaban, edoxaban, and betrixaban in the following ...
Direct thrombin inhibitors are one such class of novel anticoagulant. Initially, they were developed as parenteral agents and, more recently, as oral drugs. We review three direct...
Dabigatran, a direct thrombin inhibitor, and rivaroxaban, apixaban and edoxaban, the factor Xa inhibitors, produce a more predictable, less labile anticoagulant effect; they have been shown to be at least as safe and effective as warfarin in stroke prevention in AF.